AMGEN INC (AMGN) Stock Price, Quote, News and Overview
NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
AMGN Quote, Performance and Key Statistics
309.72
+6.71 (+2.21%)
The current stock price of AMGN is 309.72 USD. In the past month the price increased by 12.45%. In the past year, price increased by 10.48%.
AMGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B | ||
| INCY | INCYTE CORP | 56.07 | 14.32B |
Related stock screener links
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 26,700 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. The company operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 26700
Company Website: https://www.amgen.com/
Investor Relations: https://investors.amgen.com
Phone: 18054471000
AMGEN INC / AMGN FAQ
What is the stock price of AMGEN INC today?
The current stock price of AMGN is 309.72 USD. The price increased by 2.21% in the last trading session.
What is the ticker symbol for AMGEN INC stock?
The exchange symbol of AMGEN INC is AMGN and it is listed on the Nasdaq exchange.
On which exchange is AMGN stock listed?
AMGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AMGEN INC stock?
39 analysts have analysed AMGN and the average price target is 328.08 USD. This implies a price increase of 5.93% is expected in the next year compared to the current price of 309.72. Check the AMGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AMGEN INC worth?
AMGEN INC (AMGN) has a market capitalization of 166.32B USD. This makes AMGN a Large Cap stock.
How many employees does AMGEN INC have?
AMGEN INC (AMGN) currently has 26700 employees.
What are the support and resistance levels for AMGEN INC (AMGN) stock?
AMGEN INC (AMGN) has a support level at 297.24 and a resistance level at 319.04. Check the full technical report for a detailed analysis of AMGN support and resistance levels.
Is AMGEN INC (AMGN) expected to grow?
The Revenue of AMGEN INC (AMGN) is expected to grow by 5.92% in the next year. Check the estimates tab for more information on the AMGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AMGEN INC (AMGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMGN, evaluating the profitability, health, valuation and growth aspects
- AMGEN INC (AMGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AMGEN INC (AMGN) Sales and EPS estimates to see what analysts future expectations are.
- AMGEN INC (AMGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AMGEN INC (AMGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- AMGEN INC (AMGN) Stock Chart to make your own analysis
- AMGEN INC (AMGN) Latest news and press-releases to stay up to date.
Does AMGEN INC (AMGN) stock pay dividends?
AMGEN INC (AMGN) has a dividend yield of 3.2%. The yearly dividend amount is currently 9.01. Check the full fundamental report for a detailed analysis of AMGN dividend history, reliability and sustainability.
When does AMGEN INC (AMGN) report earnings?
AMGEN INC (AMGN) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of AMGEN INC (AMGN)?
The PE ratio for AMGEN INC (AMGN) is 15.63. This is based on the reported non-GAAP earnings per share of 19.82 and the current share price of 309.72 USD. Check the full fundamental report for a full analysis of the valuation metrics for AMGN.
What is the Short Interest ratio of AMGEN INC (AMGN) stock?
The outstanding short interest for AMGEN INC (AMGN) is 2.38% of its float. Check the ownership tab for more information on the AMGN short interest.
AMGN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN is one of the better performing stocks in the market, outperforming 79.72% of all stocks.
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. While AMGN has a great profitability rating, there are some minor concerns on its financial health.
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 19.82. The EPS increased by 6.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.24% | ||
| ROA | 4.45% | ||
| ROE | 69.59% | ||
| Debt/Equity | 9.62 |
AMGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to AMGN. The Buy consensus is the average rating of analysts ratings from 39 analysts.
For the next year, analysts expect an EPS growth of 6.15% and a revenue growth 5.92% for AMGN